Role of Genetic Polymorphisms in Individual Variations in Drug Response

Authors

  • Neha Priyadarshini Chaudhary

Keywords:

Pharmacogenetics, Genetic Polymorphisms, Drug Metabolism, CYP450, Pharmacogenomics, Personalized Medicine, Adverse Drug Reactions, Precision Therapeutics

Abstract

Interindividual variability in drug response remains a major challenge to safe and effective pharmacotherapy. Genetic polymorphisms in genes encoding drug-metabolizing enzymes, transporters, therapeutic targets, and immune recognition proteins contribute to differences in drug exposure, efficacy, and adverse reactions. This narrative review synthesizes published international evidence concerning the molecular basis and clinical relevance of pharmacogenetic variation. Six domains are considered: the biological foundations of polymorphism; cytochrome P450 variation; cardiovascular pharmacogenetics; oncology and analgesic prescribing; HLA-associated hypersensitivity; and clinical implementation. Well-established gene–drug associations include CYP2C19 with clopidogrel, CYP2C9 and VKORC1 with warfarin, SLCO1B1 with statin-associated toxicity, TPMT and NUDT15 with thiopurines, DPYD with fluoropyrimidines, and selected HLA alleles with severe drug reactions. Although preemptive testing has demonstrated clinical promise, not every genetic association is actionable, and the predictive value of genetic results depends on clinical context, ancestry-inclusive test design, concurrent medicines, and physiological factors. Integrating validated pharmacogenetic guidance with clinical judgment offers an important route toward more individualized prescribing.

Views: 0Downloads: 0

Downloads

Download data is not yet available.

References

Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526, 343–350. https://doi.org/10.1038/nature15817

Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. Nature, 429, 464–468. https://doi.org/10.1038/nature02626

Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., & Klein, T. E. (2021). An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 110(3), 563–572. https://doi.org/10.1002/cpt.2350

Caudle, K. E., et al. (2017). Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium. Genetics in Medicine, 19(2), 215–223. https://doi.org/10.1038/gim.2016.87

Swen, J. J., et al. (2011). Pharmacogenetics: From bench to byte—An update of guidelines. Clinical Pharmacology & Therapeutics, 89(5), 662–673. https://doi.org/10.1038/clpt.2011.34

Crews, K. R., et al. (2021). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clinical Pharmacology & Therapeutics, 110(4), 888–896. https://doi.org/10.1002/cpt.2149

Crews, K. R., et al. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clinical Pharmacology & Therapeutics, 95(4), 376–382. https://doi.org/10.1038/clpt.2013.254

Bousman, C. A., et al. (2023). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51–68. https://doi.org/10.1002/cpt.2903

Lee, C. R., et al. (2022). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics, 112(5), 959–967. https://doi.org/10.1002/cpt.2526

Mega, J. L., et al. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360(4), 354–362. https://doi.org/10.1056/NEJMoa0809171

Simon, T., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. The New England Journal of Medicine, 360(4), 363–375. https://doi.org/10.1056/NEJMoa0808227

Paré, G., et al. (2010). Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. The New England Journal of Medicine, 363(18), 1704–1714. https://doi.org/10.1056/NEJMoa1008410

International Warfarin Pharmacogenetics Consortium. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine, 360(8), 753–764. https://doi.org/10.1056/NEJMoa0809329

Pirmohamed, M., et al. (2013). A randomized trial of genotype-guided dosing of warfarin. The New England Journal of Medicine, 369(24), 2294–2303. https://doi.org/10.1056/NEJMoa1311386

SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy—A genomewide study. The New England Journal of Medicine, 359(8), 789–799. https://doi.org/10.1056/NEJMoa0801936

Relling, M. V., et al. (2019). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clinical Pharmacology & Therapeutics, 105(5), 1095–1105. https://doi.org/10.1002/cpt.1304

Maillard, M., et al. (2026). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. Clinical Pharmacology & Therapeutics, 119(4), 916–927. https://doi.org/10.1002/cpt.70209

Amstutz, U., et al. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clinical Pharmacology & Therapeutics, 103(2), 210–216. https://doi.org/10.1002/cpt.911

Deenen, M. J., et al. (2016). Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: A safety and cost analysis. Journal of Clinical Oncology, 34(3), 227–234. https://doi.org/10.1200/JCO.2015.63.1325

Kimmel, S. E., et al. (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. The New England Journal of Medicine, 369(24), 2283–2293. https://doi.org/10.1056/NEJMoa1310669

Mallal, S., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine, 358(6), 568–579. https://doi.org/10.1056/NEJMoa0706135

Chung, W.-H., et al. (2004). A marker for Stevens–Johnson syndrome. Nature, 428, 486. https://doi.org/10.1038/428486a

Chessman, D., et al. (2008). Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 28(6), 822–832. https://doi.org/10.1016/j.immuni.2008.04.020

Phillips, E. J., et al. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clinical Pharmacology & Therapeutics, 103(4), 574–581. https://doi.org/10.1002/cpt.1004

Saito, Y., et al. (2016). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen B genotype and allopurinol dosing: 2015 update. Clinical Pharmacology & Therapeutics, 99(1), 36–37. https://doi.org/10.1002/cpt.161

Swen, J. J., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, 401(10374), 347–356. https://doi.org/10.1016/S0140-6736(22)01841-4

Dunnenberger, H. M., et al. (2015). Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. Annual Review of Pharmacology and Toxicology, 55, 89–106. https://doi.org/10.1146/annurev-pharmtox-010814-124835

Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464–467. https://doi.org/10.1038/clpt.2010.279

Hershfield, M. S., et al. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clinical Pharmacology & Therapeutics, 93(2), 153–158. https://doi.org/10.1038/clpt.2012.209

Gammal, R. S., et al. (2022). The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms. Clinical Pharmacology & Therapeutics, 111(5), 1007–1021. https://doi.org/10.1002/cpt.2557

Downloads

Published

2020-04-30

How to Cite

Neha Priyadarshini Chaudhary. (2020). Role of Genetic Polymorphisms in Individual Variations in Drug Response. Birat Journal of Health Sciences, 5(1), 1-8. https://www.bjhsnepal.org/index.php/bjhs/article/view/55